Cerebra AI

Pre-clinical

San Francisco, United StatesFounded 2020cerebraai.ai

Cerebra AI's mission is to create AI solutions that are essential, not just 'nice to have,' in emergency medicine, aiming to improve outcomes when every second counts. Founded from an AI lab in Kazakhstan, the company has achieved significant milestones including regulatory approval in Kazakhstan, deployment in over 50 hospitals, and a growing proprietary dataset of over 150,000 patients. With a strategic relocation to the U.S. and a pending FDA submission, Cerebra AI is positioning itself to become a key player in the global AI-powered neuroimaging diagnostics market.

Founded

2020

Employees

70-100

Focus

AI / Machine Learning

AI Company Overview

Technology Platform

A proprietary AI software platform that analyzes standard Non-Contrast CT (NCCT) scans to automatically detect, quantify, and visualize critical pathologies like ischemic stroke and intracerebral hemorrhage, aiming to accelerate and improve diagnostic accuracy in emergency settings.

Opportunities

The massive global burden of stroke and the universal use of Non-Contrast CT in emergency rooms create a vast addressable market.

Success in the U.S.

via FDA clearance could lead to expansion into other developed markets (EU, Japan).

The company's NCCT-focused approach also presents an opportunity in resource-limited settings and community hospitals without advanced imaging capabilities.

Risk Factors

Primary risks include failure to obtain U.S.

FDA clearance, intense competition from well-established AI imaging rivals in the stroke space, challenges in proving improved patient outcomes to drive adoption, and the capital-intensive nature of U.S.

market entry and commercialization.

Competitive Landscape

Cerebra AI competes in the AI neuroimaging space against companies like Viz.ai, RapidAI, Aidoc, and Brainomix. Its key potential differentiators are a focused algorithm for standard Non-Contrast CT (widest availability), a large proprietary dataset from real-world use, and deep clinical integration experience from its initial deployment in Kazakhstan.